The test's objective was to see if the procedure can be carried out with the new endoscope. According to Medigus, if the technology progresses to a finished product, it can replace existing surgical procedure for sufferers of problems in the middle ear, without the need to perforate the ear drum. Another objective of the test was to examine the first usage of the endoscope.
Medigus will now apply for an ethics (Helsinki) committee authorization for human clinical trials.
Shares in Medigus rose 2.52% by early afternoon to NIS 1.66. The shares rose 20.7% in January.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments